Aethlon Medical to Release Third Quarter Financial Results and Host a Conference Call on February 14, 2022 |

SAN DIEGO, January 31, 2022 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, announced today that it will report financial results for its third quarter of the 2022 financial year ended December 31, 2021at 4:15 p.m. EST on Monday, February 14, 2022.

Management will hold a conference call on Monday, February 14, 2022 at 4:30 p.m. EST to review financial results and recent company developments. Following formal remarks from management, there will be a question and answer session.

Interested parties can register for the conference by accessing Please note that registered participants will receive their call number upon registration.

Interested persons without Internet access or unable to pre-register can connect by calling:



All callers should request the conference call from Aethlon Medical, Inc.

A replay of the call will be available approximately one hour after the call ends via March 14, 2022. The replay can be accessed via the Aethlon Medical website or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID is 2728183.

About Aethlon and the Hemopurifier®

Aethlon Medical is a biotechnology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer, as its lead technology. In human studies, the Hemopurifier has been shown to remove life-threatening viruses and harmful exosomes from the blood using proprietary lectin-based technology. This action has applications in cancer, where exosomes can promote immune suppression and metastasis, and in life-threatening infectious diseases.

The Hemopurifier is a breakthrough device designated by the United States Food and Drug Administration (FDA), indicated for the treatment of people with advanced or metastatic cancer who do not respond to or tolerate standard treatment of care, and with types of cancer in which exosomes have been shown to participate in the development or severity of disease. As part of an investigational device exemption (IDE) application, the FDA has approved a single-site, open-label early feasibility study (EFS) to evaluate the hemopurifier for reducing cancer-associated exosomes prior to administration reference pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is conducted at University of Pittsburgh Hillman Cancer Center Medical Center.

The Hemopurifier also holds an FDA Breakthrough Device designation and an open application IDE related to the treatment of life-threatening viruses that are not treated with approved therapies. A recent amendment to the IDE allowed Aethlon to implement a new EFS protocol to treat up to 40 COVID-19 patients at up to 20 clinical sites in the United States. In two case studies of patients treated under emergency use (EU), hemopurification of SARS-CoV-2 spike protein and elimination of SARS-CoV-2 virus from the circulating d a human patient.

Additional information is available at

Company Contact:

Jim Frakes

Financial director

Aethlon Medical, Inc.

[email protected]

Media Contact:

Tony Russodoctorate

Russo Partners, LLC

[email protected]


Investor contacts:

Susan Nounan

S.A. Noonan Communications, LLC

[email protected]


View original content: – 301471097.html

SOURCEAethlon Medical, Inc.

Michael P. Boser